Revelation Biosciences
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting th...
Latest News
1 month ago · gurufocus.com
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026[url="]Revelation Biosciences, Inc.[/url] (NASDAQ: REVB) (the âCompanyâ or âRevelationâ), a clinical-stage life sciences company developing innovative s
3 months ago · businesswire.com
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudySAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design TITAN study for evaluating Gemini in patients with acute kidney injury (AKI). The importance of hiring.
Add to Watchlist
Select watchlists to add or remove REVB